 | • レポートコード：MMG23DC12449 • 出版社/出版日：Market Monitor Global / 2023年12月 • レポート形態：英語、PDF、68ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User（1名様閲覧用） | ￥487,500 (USD3,250) | ▷ お問い合わせ |
| Multi User（20名様閲覧用） | ￥633,750 (USD4,225) | ▷ お問い合わせ |
| Enterprise User（閲覧人数制限なし） | ￥731,250 (USD4,875) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査レポートは次の情報を含め、世界のTHR-βアゴニスト市場規模と予測を収録しています。・世界のTHR-βアゴニスト市場：売上、2018年-2023年、2024年-2029年 ・世界のTHR-βアゴニスト市場：販売量、2018年-2023年、2024年-2029年 ・世界のトップ5企業、2022年 世界のTHR-βアゴニスト市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「仕様10mg以下」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。 THR-βアゴニストのグローバル主要企業は、Madrigal Pharmaceuticals、 Terns Pharmaceuticals、 Ascletis、 Haisco Pharmaceutical Groupなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。 MARKET MONITOR GLOBAL（MMG）は、THR-βアゴニストのメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。 【セグメント別市場分析】 世界のTHR-βアゴニスト市場：タイプ別、2018年-2023年、2024年-2029年 世界のTHR-βアゴニスト市場：タイプ別市場シェア、2022年 ・仕様10mg以下、仕様10-50mg、仕様50mg以上 世界のTHR-βアゴニスト市場：用途別、2018年-2023年、2024年-2029年 世界のTHR-βアゴニスト市場：用途別市場シェア、2022年 ・代謝性疾患、循環器疾患、その他 世界のTHR-βアゴニスト市場：地域・国別、2018年-2023年、2024年-2029年 世界のTHR-βアゴニスト市場：地域別市場シェア、2022年 ・北米：アメリカ、カナダ、メキシコ ・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア ・アジア：中国、日本、韓国、東南アジア、インド ・南米：ブラジル、アルゼンチン ・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE 【競合分析】 また、当レポートは主要な市場参加者の分析を提供します。 ・主要企業におけるTHR-βアゴニストのグローバル売上、2018年-2023年 ・主要企業におけるTHR-βアゴニストのグローバル売上シェア、2022年 ・主要企業におけるTHR-βアゴニストのグローバル販売量、2018年-2023年 ・主要企業におけるTHR-βアゴニストのグローバル販売量シェア、2022年 さらに、当レポートは主要企業のプロファイルを提示します。 Madrigal Pharmaceuticals、 Terns Pharmaceuticals、 Ascletis、 Haisco Pharmaceutical Group ************************************************************* ・調査・分析レポートの概要 THR-βアゴニスト市場の定義 市場セグメント 世界のTHR-βアゴニスト市場概要 当レポートの特徴・ベネフィット 調査手法と情報源 ・世界のTHR-βアゴニスト市場規模 世界のTHR-βアゴニスト市場規模：2022年 VS 2029年 世界のTHR-βアゴニスト市場規模と予測 2018年-2029年 ・競争状況 グローバルトップ企業 売上ベースでのグローバルトップ企業 企業別グローバルでのTHR-βアゴニストの売上 グローバルトップ3およびトップ5企業、2022年売上ベース グローバル企業のTHR-βアゴニスト製品タイプ グローバルにおけるティア1、ティア2、ティア3企業 ・タイプ別市場分析 タイプ区分：仕様10mg以下、仕様10-50mg、仕様50mg以上 THR-βアゴニストのタイプ別グローバル売上・予測 ・用途別市場分析 用途区分：代謝性疾患、循環器疾患、その他 THR-βアゴニストの用途別グローバル売上・予測 ・地域別市場分析 地域別THR-βアゴニスト市場規模 2022年と2029年 地域別THR-βアゴニスト売上・予測 北米市場：アメリカ、カナダ、メキシコ ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア アジア市場：中国、日本、韓国、東南アジア、インド 南米市場：ブラジル、アルゼンチン 中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE ・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど） Madrigal Pharmaceuticals、 Terns Pharmaceuticals、 Ascletis、 Haisco Pharmaceutical Group ... |
This research report provides a comprehensive analysis of the THR- β Agonists market, focusing on the current trends, market dynamics, and future prospects. The report explores the global THR- β Agonists market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of THR- β Agonists, challenges faced by the industry, and potential opportunities for market players.
The global THR- β Agonists market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The THR- β Agonists market presents opportunities for various stakeholders, including Metabolic Diseases, Cardiovascular Disease. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in THR- β Agonists market. Additionally, the growing consumer demand present avenues for market expansion.
The global THR- β Agonists market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period.
Key Features:
The research report on the THR- β Agonists market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the THR- β Agonists market.
Market Overview: The report provides a comprehensive overview of the THR- β Agonists market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., Specification Below 10mg, Specification 10-50mg), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the THR- β Agonists market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the THR- β Agonists market’s trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the THR- β Agonists market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the THR- β Agonists market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the THR- β Agonists market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the THR- β Agonists market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for THR- β Agonists, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the THR- β Agonists market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
THR- β Agonists market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
Specification Below 10mg
Specification 10-50mg
Specification Above 50mg
Market segment by Application
Metabolic Diseases
Cardiovascular Disease
Others
Global THR- β Agonists Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Major players covered
Madrigal Pharmaceuticals
Terns Pharmaceuticals
Ascletis
Haisco Pharmaceutical Group
Outline of Major Chapters:
Chapter 1: Introduces the definition of THR- β Agonists, market overview.
Chapter 2: Global THR- β Agonists market size in revenue.
Chapter 3: Detailed analysis of THR- β Agonists company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of THR- β Agonists in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
1 Introduction to Research & Analysis Reports
1.1 THR- β Agonists Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global THR- β Agonists Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global THR- β Agonists Overall Market Size
2.1 Global THR- β Agonists Market Size: 2022 VS 2029
2.2 Global THR- β Agonists Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top THR- β Agonists Players in Global Market
3.2 Top Global THR- β Agonists Companies Ranked by Revenue
3.3 Global THR- β Agonists Revenue by Companies
3.4 Top 3 and Top 5 THR- β Agonists Companies in Global Market, by Revenue in 2022
3.5 Global Companies THR- β Agonists Product Type
3.6 Tier 1, Tier 2 and Tier 3 THR- β Agonists Players in Global Market
3.6.1 List of Global Tier 1 THR- β Agonists Companies
3.6.2 List of Global Tier 2 and Tier 3 THR- β Agonists Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type – Global THR- β Agonists Market Size Markets, 2022 & 2029
4.1.2 Specification Below 10mg
4.1.3 Specification 10-50mg
4.1.4 Specification Above 50mg
4.2 By Type – Global THR- β Agonists Revenue & Forecasts
4.2.1 By Type – Global THR- β Agonists Revenue, 2018-2023
4.2.2 By Type – Global THR- β Agonists Revenue, 2024-2029
4.2.3 By Type – Global THR- β Agonists Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global THR- β Agonists Market Size, 2022 & 2029
5.1.2 Metabolic Diseases
5.1.3 Cardiovascular Disease
5.1.4 Others
5.2 By Application – Global THR- β Agonists Revenue & Forecasts
5.2.1 By Application – Global THR- β Agonists Revenue, 2018-2023
5.2.2 By Application – Global THR- β Agonists Revenue, 2024-2029
5.2.3 By Application – Global THR- β Agonists Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region – Global THR- β Agonists Market Size, 2022 & 2029
6.2 By Region – Global THR- β Agonists Revenue & Forecasts
6.2.1 By Region – Global THR- β Agonists Revenue, 2018-2023
6.2.2 By Region – Global THR- β Agonists Revenue, 2024-2029
6.2.3 By Region – Global THR- β Agonists Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country – North America THR- β Agonists Revenue, 2018-2029
6.3.2 US THR- β Agonists Market Size, 2018-2029
6.3.3 Canada THR- β Agonists Market Size, 2018-2029
6.3.4 Mexico THR- β Agonists Market Size, 2018-2029
6.4 Europe
6.4.1 By Country – Europe THR- β Agonists Revenue, 2018-2029
6.4.2 Germany THR- β Agonists Market Size, 2018-2029
6.4.3 France THR- β Agonists Market Size, 2018-2029
6.4.4 U.K. THR- β Agonists Market Size, 2018-2029
6.4.5 Italy THR- β Agonists Market Size, 2018-2029
6.4.6 Russia THR- β Agonists Market Size, 2018-2029
6.4.7 Nordic Countries THR- β Agonists Market Size, 2018-2029
6.4.8 Benelux THR- β Agonists Market Size, 2018-2029
6.5 Asia
6.5.1 By Region – Asia THR- β Agonists Revenue, 2018-2029
6.5.2 China THR- β Agonists Market Size, 2018-2029
6.5.3 Japan THR- β Agonists Market Size, 2018-2029
6.5.4 South Korea THR- β Agonists Market Size, 2018-2029
6.5.5 Southeast Asia THR- β Agonists Market Size, 2018-2029
6.5.6 India THR- β Agonists Market Size, 2018-2029
6.6 South America
6.6.1 By Country – South America THR- β Agonists Revenue, 2018-2029
6.6.2 Brazil THR- β Agonists Market Size, 2018-2029
6.6.3 Argentina THR- β Agonists Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country – Middle East & Africa THR- β Agonists Revenue, 2018-2029
6.7.2 Turkey THR- β Agonists Market Size, 2018-2029
6.7.3 Israel THR- β Agonists Market Size, 2018-2029
6.7.4 Saudi Arabia THR- β Agonists Market Size, 2018-2029
6.7.5 UAE THR- β Agonists Market Size, 2018-2029
7 THR- β Agonists Companies Profiles
7.1 Madrigal Pharmaceuticals
7.1.1 Madrigal Pharmaceuticals Company Summary
7.1.2 Madrigal Pharmaceuticals Business Overview
7.1.3 Madrigal Pharmaceuticals THR- β Agonists Major Product Offerings
7.1.4 Madrigal Pharmaceuticals THR- β Agonists Revenue in Global Market (2018-2023)
7.1.5 Madrigal Pharmaceuticals Key News & Latest Developments
7.2 Terns Pharmaceuticals
7.2.1 Terns Pharmaceuticals Company Summary
7.2.2 Terns Pharmaceuticals Business Overview
7.2.3 Terns Pharmaceuticals THR- β Agonists Major Product Offerings
7.2.4 Terns Pharmaceuticals THR- β Agonists Revenue in Global Market (2018-2023)
7.2.5 Terns Pharmaceuticals Key News & Latest Developments
7.3 Ascletis
7.3.1 Ascletis Company Summary
7.3.2 Ascletis Business Overview
7.3.3 Ascletis THR- β Agonists Major Product Offerings
7.3.4 Ascletis THR- β Agonists Revenue in Global Market (2018-2023)
7.3.5 Ascletis Key News & Latest Developments
7.4 Haisco Pharmaceutical Group
7.4.1 Haisco Pharmaceutical Group Company Summary
7.4.2 Haisco Pharmaceutical Group Business Overview
7.4.3 Haisco Pharmaceutical Group THR- β Agonists Major Product Offerings
7.4.4 Haisco Pharmaceutical Group THR- β Agonists Revenue in Global Market (2018-2023)
7.4.5 Haisco Pharmaceutical Group Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
Table 1. THR- β Agonists Market Opportunities & Trends in Global Market
Table 2. THR- β Agonists Market Drivers in Global Market
Table 3. THR- β Agonists Market Restraints in Global Market
Table 4. Key Players of THR- β Agonists in Global Market
Table 5. Top THR- β Agonists Players in Global Market, Ranking by Revenue (2022)
Table 6. Global THR- β Agonists Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global THR- β Agonists Revenue Share by Companies, 2018-2023
Table 8. Global Companies THR- β Agonists Product Type
Table 9. List of Global Tier 1 THR- β Agonists Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 THR- β Agonists Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type – Global THR- β Agonists Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - THR- β Agonists Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - THR- β Agonists Revenue in Global (US$, Mn), 2024-2029
Table 14. By Application – Global THR- β Agonists Revenue, (US$, Mn), 2022 & 2029
Table 15. By Application - THR- β Agonists Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - THR- β Agonists Revenue in Global (US$, Mn), 2024-2029
Table 17. By Region – Global THR- β Agonists Revenue, (US$, Mn), 2022 & 2029
Table 18. By Region - Global THR- β Agonists Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global THR- β Agonists Revenue (US$, Mn), 2024-2029
Table 20. By Country - North America THR- β Agonists Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America THR- β Agonists Revenue, (US$, Mn), 2024-2029
Table 22. By Country - Europe THR- β Agonists Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe THR- β Agonists Revenue, (US$, Mn), 2024-2029
Table 24. By Region - Asia THR- β Agonists Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia THR- β Agonists Revenue, (US$, Mn), 2024-2029
Table 26. By Country - South America THR- β Agonists Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America THR- β Agonists Revenue, (US$, Mn), 2024-2029
Table 28. By Country - Middle East & Africa THR- β Agonists Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa THR- β Agonists Revenue, (US$, Mn), 2024-2029
Table 30. Madrigal Pharmaceuticals Company Summary
Table 31. Madrigal Pharmaceuticals THR- β Agonists Product Offerings
Table 32. Madrigal Pharmaceuticals THR- β Agonists Revenue (US$, Mn) & (2018-2023)
Table 33. Madrigal Pharmaceuticals Key News & Latest Developments
Table 34. Terns Pharmaceuticals Company Summary
Table 35. Terns Pharmaceuticals THR- β Agonists Product Offerings
Table 36. Terns Pharmaceuticals THR- β Agonists Revenue (US$, Mn) & (2018-2023)
Table 37. Terns Pharmaceuticals Key News & Latest Developments
Table 38. Ascletis Company Summary
Table 39. Ascletis THR- β Agonists Product Offerings
Table 40. Ascletis THR- β Agonists Revenue (US$, Mn) & (2018-2023)
Table 41. Ascletis Key News & Latest Developments
Table 42. Haisco Pharmaceutical Group Company Summary
Table 43. Haisco Pharmaceutical Group THR- β Agonists Product Offerings
Table 44. Haisco Pharmaceutical Group THR- β Agonists Revenue (US$, Mn) & (2018-2023)
Table 45. Haisco Pharmaceutical Group Key News & Latest Developments
List of Figures
Figure 1. THR- β Agonists Segment by Type in 2022
Figure 2. THR- β Agonists Segment by Application in 2022
Figure 3. Global THR- β Agonists Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global THR- β Agonists Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global THR- β Agonists Revenue, 2018-2029 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by THR- β Agonists Revenue in 2022
Figure 8. By Type - Global THR- β Agonists Revenue Market Share, 2018-2029
Figure 9. By Application - Global THR- β Agonists Revenue Market Share, 2018-2029
Figure 10. By Type - Global THR- β Agonists Revenue, (US$, Mn), 2022 & 2029
Figure 11. By Type - Global THR- β Agonists Revenue Market Share, 2018-2029
Figure 12. By Application - Global THR- β Agonists Revenue, (US$, Mn), 2022 & 2029
Figure 13. By Application - Global THR- β Agonists Revenue Market Share, 2018-2029
Figure 14. By Region - Global THR- β Agonists Revenue Market Share, 2018-2029
Figure 15. By Country - North America THR- β Agonists Revenue Market Share, 2018-2029
Figure 16. US THR- β Agonists Revenue, (US$, Mn), 2018-2029
Figure 17. Canada THR- β Agonists Revenue, (US$, Mn), 2018-2029
Figure 18. Mexico THR- β Agonists Revenue, (US$, Mn), 2018-2029
Figure 19. By Country - Europe THR- β Agonists Revenue Market Share, 2018-2029
Figure 20. Germany THR- β Agonists Revenue, (US$, Mn), 2018-2029
Figure 21. France THR- β Agonists Revenue, (US$, Mn), 2018-2029
Figure 22. U.K. THR- β Agonists Revenue, (US$, Mn), 2018-2029
Figure 23. Italy THR- β Agonists Revenue, (US$, Mn), 2018-2029
Figure 24. Russia THR- β Agonists Revenue, (US$, Mn), 2018-2029
Figure 25. Nordic Countries THR- β Agonists Revenue, (US$, Mn), 2018-2029
Figure 26. Benelux THR- β Agonists Revenue, (US$, Mn), 2018-2029
Figure 27. By Region - Asia THR- β Agonists Revenue Market Share, 2018-2029
Figure 28. China THR- β Agonists Revenue, (US$, Mn), 2018-2029
Figure 29. Japan THR- β Agonists Revenue, (US$, Mn), 2018-2029
Figure 30. South Korea THR- β Agonists Revenue, (US$, Mn), 2018-2029
Figure 31. Southeast Asia THR- β Agonists Revenue, (US$, Mn), 2018-2029
Figure 32. India THR- β Agonists Revenue, (US$, Mn), 2018-2029
Figure 33. By Country - South America THR- β Agonists Revenue Market Share, 2018-2029
Figure 34. Brazil THR- β Agonists Revenue, (US$, Mn), 2018-2029
Figure 35. Argentina THR- β Agonists Revenue, (US$, Mn), 2018-2029
Figure 36. By Country - Middle East & Africa THR- β Agonists Revenue Market Share, 2018-2029
Figure 37. Turkey THR- β Agonists Revenue, (US$, Mn), 2018-2029
Figure 38. Israel THR- β Agonists Revenue, (US$, Mn), 2018-2029
Figure 39. Saudi Arabia THR- β Agonists Revenue, (US$, Mn), 2018-2029
Figure 40. UAE THR- β Agonists Revenue, (US$, Mn), 2018-2029
Figure 41. Madrigal Pharmaceuticals THR- β Agonists Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Terns Pharmaceuticals THR- β Agonists Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Ascletis THR- β Agonists Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Haisco Pharmaceutical Group THR- β Agonists Revenue Year Over Year Growth (US$, Mn) & (2018-2023)